Objectives: SUSTAIN is a prospective, multi-center non-interventional study in Germany to observe long term efficacy and safety, quality of life and further patient reported outcomes in patients with active psoriatic arthritis under treatment with Ustekinumab in routine clinical care. Methods: In this study treatment with Ustekinumab is according to the label (Stelara ® ). It is planned to observe 400 patients at 75 centers for 160 weeks with documentation intervals at week 0 and 4 and then every 12 weeks. Besides demographic data, the following data will be documented: Amount of swollen and tender joints, tender entheses, skin symptoms (BSA and PASI), patient reported outcome concerning disease activity and pain, Health Assessment Questionnaire (HAQ), quality of life (SF-12), sleep quality (VAS), satisfaction with therapy of patient and physician, safety (adverse events [AE]/serious adverse events [SAE]), pharmacoeconomic aspects, number of patients with "Minimal Disease Activity" (MDA), number of patients with MDA at week 28 und 52. Results: Overall, there have been 189 patients (56% women) at 59 centers documented after 11 months. At week 4 154 patients and at week 16 112 patients. At baseline, the patients had a mean age of 56 years (29-85), body weight 87 kg (50-147), BMI 30 (19-47), showed arthritis at small (68.8%) and/or big (51.3%) joints, skeletal involvement (19%), enthesitis (13.2%). The number of tender joints improved from a mean of 8,6 (CI 95% 7.1/10.2) to 4.7 (3.1/6.3) at week 16, number of swollen joints from 3,4 (2,6/4,2) to 1,4 (0.9/1.9). The patient reported global disease activity (0-100) decreased from 55.1 to 38.6 at week 16. Further improvements were documented for enthesitis, PSA, BSA, PASI, and pain. Efficacy of the therapy with Ustekinumab after 16 weeks was assessed as "very good" by 32.3% and as "good" by 44.8% of the treating physicians and by 34% and 40.2%, respectively, of the patients. In total, 60 adverse events were reported, of which four were serious. All in all safety of therapy with Ustekinumab after 16 weeks was assessed as "very good" by 51% and as "good" by 43.8% of the treating physicians, and by 55% and 37%, respectively, of the patients.
Conclusions:
The non-interventional study SUSTAIN showed relevant improvements with elevated therapy satisfaction and good safety in patients with active psoriatic arthritis after 16 weeks under real world condition. 
Methods:
We included all PsA patients (CASPAR criteria) under treatment with BD followed in our regional registry (reference population 2.055.000) between January 2011 and December 2015. In order to capture the incidence of new malignancy we excluded patients with a prior history of malignancy. Medical records were fulfilled for patients and were recorded solid tumors diagnosed (date of diagnosis and histology information) and all serious infections (requiring hospitalization or intravenous antibiotics) in this time. Incidence rates (IRs) were calculated per 1000 Person-year (py). We used for this analysis sex, age, disease duration, current BD with or without current DMARD associated. Continuous variables were reported as mean ± standard deviation (SD). Categorical variables were reported as percentages and frequencies. Differences were considered statistically significant if p<0.05 (two-tailed). Results: Among 604 patients 329 (54.5%) of whom were men, with a mean age of 53.3±12.6 years and a time since the diagnosis of PsA of 12.4±8.7 years. There were 14 cancers diagnosed during treatment (2.3%), with an IR of 0.48 cases per 1000 patient-years. Patients who developed cancer had a higher age, 63.4±10.0 years vs 53.1±12.6, than those who did not developed (p=0.010). Etanercept was the most used (42%) and no differences were observed among BDs (p=0.214) or between naïve and non-naïve to BD (p=0.384). Current DMARD associated (56.2%) had not differences in tumors (p=0.429). Prostate tumor was the most frequent (21.4%). There were 42 had serious infection (6.2%), with an IR of 13.9 cases per 1000 patient-years, and was more common in men (4.7% vs 8.8%, p=0.049). Severe infections were more frequent in patients non-naïve to BD (10.4% vs 5.4%, p=0.026). Pneumonia (28.6%), varicella-zoster virus infection (16.6%) and soft tissue infections (14.3%) were most frequent. Latent tuberculosis infection was positive in 133 patients (22.0%) and 3 developed tuberculosis. Conclusions: Patients older than 60 years with psoriatic arthritis treated with BDs had a higher incidence of tumor development. Most of patients were men and prostate tumor was the most frequent. Pneumonia was the most frequent serious infection and non-naïve to BD patients had a higher IR of serious infections. References: [1] Malignancy incidence in patients with psoriatic arthritis: a comparison cohortbased incidence study. Objectives: To explore the relationship between DAPSA states and function, health-related quality of life and PROs, and the individual DAPSA components in the different states in pts treated with secukinumab through 104 wks using post-hoc analysis. Methods: FUTURE 2 study design has been reported. 3 DAPSA was derived as sum of five core components: tender joint and swollen joint counts (TJC 68, SJC 66), pt global assessment (PtGA) and pain (PP) assessed by a 10cm VAS and CRP (mg/dl). Four DAPSA states were: remission (REM:≤4), low (LDA:>4-≤14), moderate (MDA:>14-≤28) or high disease activity (HDA:>28). Mean±SD of each core component of DAPSA were analysed at Wks 16, 24, 52 and 104 using observed data. The relationship between HAQ-DI, SF-36 PCS and MCS, PsAQoL, DLQI and FACIT-Fatigue with DAPSA states was assessed in the pooled treatment arms at each time point using a mixed-effect model for repeated measures (MMRM) analyses. Results: Baseline characteristics were similar across treatment groups.
3 DAPSA scores at baseline (mean±SD) were 42.0±17.4, 46.8±24.3 and 44.9±25.3 in the secukinumab 300mg, 150mg and placebo groups, respectively. Mean scores of each component by DAPSA states at Wk 16 are shown in table and were sustained through Wk 104. Significant differences were observed among secukinumab treated pts between REM vs. HDA and LDA vs. HDA states for PRO scores through Wk104 (Figure) .
Conclusions:
In pts treated with secukinumab 300 or 150mg, the five individual components related to DAPSA REM were <1 in contrast with other disease states and were sustained through Wk 104. DAPSA REM was associated with significantly greater improvement in physical function, health related quality of life and fatigue indicating that it is an important target to be achieved and sustained in PsA pts.
